BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

HMGene, Inc. And Suntory Pharmaceutical Research Laboratories LLC Enter Agreement For Obesity


10/19/2005 5:09:31 PM

PISCATAWAY, N.J., Dec. 16 /PRNewswire-FirstCall/ -- HMGene, Inc., a privately-held drug discovery company pioneering novel therapies for metabolic disorders, announced today that it has signed an agreement regarding one of its proprietary obesity targets with Suntory Pharmaceutical Research Laboratories LLC (SPRL), Cambridge, MA. The purpose of this agreement is to pursue the discovery and development of drugs for obesity.

Through its proprietary ADIPOSENSE(TM) technology, HMGene has identified a series of molecular targets to treat obesity. HMGene has also demonstrated that several targets identified by ADIPOSENSE(TM) can be modulated either to prevent fat deposition or to increase fat mobilization by stimulating its breakdown from fat depots. The company's collaboration with SPRL is aimed at identification of small-molecule lead compounds against one of HMGene's proprietary obesity targets. "This agreement signifies validation of our technology in this vast area of unmet therapeutic need, and we are pleased to be working with the distinguished team at SPRL," said Leland Gershell, M.D., Ph.D., HMGene's Chief Executive Officer.

HMGene is an early-stage biotechnology company dedicated to the development of novel pharmaceuticals directed toward metabolic disorders, with a focus on obesity. The seminal findings supporting HMGene's approach are the result of over ten years of research by Dr. Kiran Chada, Chief Scientific Officer of HMGene and Professor of Biochemistry at the Robert Wood Johnson Medical School in Piscataway, New Jersey. HMGene has been funded since its inception by the Small Business Innovation Research program of the National Institutes of Health.

This press release contains "forward-looking" statements, including statements related to HMGene's efforts to develop anti-obesity compounds. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of HMGene to differ materially from those indicated by these forward-looking statements, including, among others, risks and uncertainties relating to difficulties or delays in the development of the Company's drug candidates. HMGene does not undertake any obligation to update forward-looking statements.

HMGene, Inc.

CONTACT: Hena R. Ashar, Ph. D., Vice President for Research of HMGene,Inc., +1-732-235-3973, Fax: +1-732-235-3965



Read at BioSpace.com

   
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES